Simvastatin attenuates cardiac isograft ischemia-reperfusion injury by down-regulating CC chemokine receptor-2 expression.

[1]  B. Riedel,et al.  Improved Postoperative Outcomes Associated with Preoperative Statin Therapy , 2006, Anesthesiology.

[2]  E. Miller,et al.  Prevention of Neutrophil Migration Ameliorates Rat Lung Allograft Rejection , 2006, Molecular medicine.

[3]  F. Mach,et al.  Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. , 2006, Atherosclerosis.

[4]  W. Kuziel,et al.  CC chemokine receptor-2 deficiency attenuates oxidative stress and infarct size caused by myocardial ischemia-reperfusion in mice. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[5]  H. Anders,et al.  Chemokine receptors Ccr1, Ccr2, and Ccr5 mediate neutrophil migration to postischemic tissue , 2006, Journal of leukocyte biology.

[6]  P. Tsao,et al.  Prolonged cold ischemia in rat cardiac allografts promotes ischemia-reperfusion injury and the development of graft coronary artery disease in a linear fashion. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  M. Sho,et al.  A Novel Small-Molecule Compound Targeting CCR5 and CXCR3 Prevents Acute and Chronic Allograft Rejection , 2005, Transplantation.

[8]  M. Entman,et al.  Chemokines in myocardial ischemia. , 2005, Trends in cardiovascular medicine.

[9]  R. de Caterina,et al.  Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. , 2005, Cardiovascular Research.

[10]  B. Rollins,et al.  CCL2/Monocyte Chemoattractant Protein-1 Regulates Inflammatory Responses Critical to Healing Myocardial Infarcts , 2005, Circulation research.

[11]  K. Mensah,et al.  Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? , 2005, Journal of the American College of Cardiology.

[12]  Richard T. Lee,et al.  Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion. , 2005, American journal of physiology. Heart and circulatory physiology.

[13]  M. Mocanu,et al.  Atorvastatin and Myocardial Reperfusion Injury: New Pleiotropic Effect Implicating Multiple Prosurvival Signaling , 2005, Journal of cardiovascular pharmacology.

[14]  H. Drexler,et al.  Statin-Induced Improvement of Endothelial Progenitor Cell Mobilization, Myocardial Neovascularization, Left Ventricular Function, and Survival After Experimental Myocardial Infarction Requires Endothelial Nitric Oxide Synthase , 2004, Circulation.

[15]  M. Entman,et al.  Targeting the chemokines in myocardial inflammation. , 2004, Circulation.

[16]  H. Klein,et al.  Simvastatin Acutely Reduces Myocardial Reperfusion Injury In Vivo by Activating the Phosphatidylinositide 3-Kinase/Akt Pathway , 2004, Journal of cardiovascular pharmacology.

[17]  W. Kuziel,et al.  Targeted deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after experimental myocardial infarction. , 2004, The American journal of pathology.

[18]  J. Davignon.  Beneficial Cardiovascular Pleiotropic Effects of Statins , 2004, Circulation.

[19]  J. Musial,et al.  New nonlipid effects of statins and their clinical relevance in cardiovascular disease , 2004, Thrombosis and Haemostasis.

[20]  M. Entman,et al.  Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. , 2004, The American journal of pathology.

[21]  Shuiping Zhao,et al.  Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[22]  K. Matsushima,et al.  J Am Soc Nephrol 14: 2503–2515, 2003 CCR2 Signaling Contributes to Ischemia-Reperfusion Injury , 2022 .

[23]  B. Naidu,et al.  Simvastatin ameliorates injury in an experimental model of lung ischemia-reperfusion. , 2003, The Journal of thoracic and cardiovascular surgery.

[24]  F. Niroomand,et al.  Reduction of myocardial infarct size by fluvastatin. , 2003, American journal of physiology. Heart and circulatory physiology.

[25]  Yu Zhang,et al.  Pretreatment with statins enhances myocardial protection during coronary revascularization. , 2003, The Journal of thoracic and cardiovascular surgery.

[26]  K. Matsushima,et al.  Gene therapy expressing amino-terminal truncated monocyte chemoattractant protein-1 prevents renal ischemia-reperfusion injury. , 2003, Journal of the American Society of Nephrology : JASN.

[27]  W. Seeger,et al.  Monocytes Are Potent Facilitators of Alveolar Neutrophil Emigration During Lung Inflammation: Role of the CCL2-CCR2 Axis1 , 2003, The Journal of Immunology.

[28]  D. Yellon,et al.  Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. , 2003, Journal of the American College of Cardiology.

[29]  F. Luft,et al.  Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. , 2002, Journal of the American Society of Nephrology : JASN.

[30]  Michael R. Müller,et al.  Simvastatin Reduces Expression of Cytokines Interleukin-6, Interleukin-8, and Monocyte Chemoattractant Protein-1 in Circulating Monocytes From Hypercholesterolemic Patients , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[31]  L. Toledo-Pereyra,et al.  Ischemia/reperfusion injury. , 2002, The Journal of surgical research.

[32]  E. Tuzcu,et al.  Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome. , 2002, Journal of the American College of Cardiology.

[33]  J. Berman,et al.  Chemokine expression in myocardial ischemia: MIP-2 dependent MCP-1 expression protects cardiomyocytes from cell death. , 2002, Journal of molecular and cellular cardiology.

[34]  D. Lefer,et al.  Pretreatment With Simvastatin Attenuates Myocardial Dysfunction After Ischemia and Chronic Reperfusion , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[35]  A. M. Lefer,et al.  Simvastatin Exerts Both Anti-inflammatory and Cardioprotective Effects in Apolipoprotein E—Deficient Mice , 2001, Circulation.

[36]  D. Hearse,et al.  The isolated blood and perfusion fluid perfused heart. , 2000, Pharmacological research.

[37]  J. Egido,et al.  Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. , 1999, Atherosclerosis.

[38]  A. M. Lefer,et al.  Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. , 1999, Circulation.

[39]  J. Egido,et al.  HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. , 1998, Journal of the American College of Cardiology.

[40]  K Ono,et al.  Improved technique of heart transplantation in rats. , 1969, The Journal of thoracic and cardiovascular surgery.